메뉴 건너뛰기




Volumn 115, Issue 10, 2008, Pages 1214-1224

A randomised controlled trial comparing GnRH antagonist Cetrorelix with GnRH agonist Leuprorelin for endometrial thinning prior to transcervical resection of endometrium

Author keywords

Cetrorelix; Endometrial preparation; Leuprorelin; Randomised controlled trial; TCRE

Indexed keywords

CETRORELIX; LEUPRORELIN; PLACEBO; SODIUM CHLORIDE;

EID: 49649100640     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2008.01837.x     Document Type: Article
Times cited : (5)

References (20)
  • 1
    • 0029049688 scopus 로고
    • Good practice with endometrial ablation
    • Garry R. Good practice with endometrial ablation. Obst Gynaecol 1995 85 : 144 51.
    • (1995) Obst Gynaecol , vol.85 , pp. 144-51
    • Garry, R.1
  • 2
    • 84900943592 scopus 로고    scopus 로고
    • Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (Cochrane Review)
    • In: Oxford, UK: Update Software
    • Sowter MC, Lethaby A, Singla AA. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (Cochrane Review). In : The Cochrane Library. Oxford, UK : Update Software 2003.
    • (2003) The Cochrane Library.
    • Sowter, M.C.1    Lethaby, A.2    Singla, A.A.3
  • 3
    • 0028306250 scopus 로고
    • Gonadotropin-releasing hormone and its analogs
    • Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994 45 : 391 405.
    • (1994) Annu Rev Med , vol.45 , pp. 391-405
    • Conn, P.M.1    Crowley Jr., W.F.2
  • 4
    • 0029949201 scopus 로고    scopus 로고
    • A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation
    • Garry R, Khair A, Mooney P, Stuart M. A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation. Br J Obstet Gynaecol 1996 103 : 339 44.
    • (1996) Br J Obstet Gynaecol , vol.103 , pp. 339-44
    • Garry, R.1    Khair, A.2    Mooney, P.3    Stuart, M.4
  • 5
    • 0035944837 scopus 로고    scopus 로고
    • Gonadotropin-releasing hormone receptor antagonists. New drug classes
    • Huirne JAF, Lambalk CB. Gonadotropin-releasing hormone receptor antagonists. New drug classes. Lancet 2001 358 : 1793 803.
    • (2001) Lancet , vol.358 , pp. 1793-803
    • Huirne, J.A.F.1    Lambalk, C.B.2
  • 6
    • 0030730449 scopus 로고    scopus 로고
    • Treatment of uterine leiomyomas with luteinising hormone-releasing hormone antagonist cetrorelix
    • Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinising hormone-releasing hormone antagonist cetrorelix. Hum Reprod 1997 12 : 2028 35.
    • (1997) Hum Reprod , vol.12 , pp. 2028-35
    • Gonzalez-Barcena, D.1    Alvarez, R.B.2    Ochoa, E.P.3
  • 7
    • 0007003397 scopus 로고    scopus 로고
    • Initial safety profile and hormonal dose-response characteristics of the pure GnRH antagonist, abarelix-depot, in women with endometriosis
    • (abstract).
    • Martha PM, Gray ME, Campion M, et al. Initial safety profile and hormonal dose-response characteristics of the pure GnRH antagonist, abarelix-depot, in women with endometriosis. Gynaecol Endocrinol 1999 13 : 104 (abstract).
    • (1999) Gynaecol Endocrinol , vol.13 , pp. 104
    • Martha, P.M.1    Gray, M.E.2    Campion, M.3
  • 8
    • 0034047072 scopus 로고    scopus 로고
    • Inhibitory effect of luteinising-releasing hormone analogues on human endometrial cancer in vitro
    • Noci I, Coronnello M, Borri P, et al. Inhibitory effect of luteinising-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett 2000 150 : 71 8.
    • (2000) Cancer Lett , vol.150 , pp. 71-8
    • Noci, I.1    Coronnello, M.2    Borri, P.3
  • 9
    • 0028283353 scopus 로고
    • Suppression of the endogenous luteinising hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation
    • Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinising hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Human Reprod 1994 9 : 788 91.
    • (1994) Human Reprod , vol.9 , pp. 788-91
    • Diedrich, K.1    Diedrich, C.2    Santos, E.3
  • 10
    • 0028038145 scopus 로고
    • Single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilisation embryo transfer program
    • Olivennes F, Franchin R, Bouchard P, et al. Single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilisation embryo transfer program. Fertil Steril 1994 62 : 468 76.
    • (1994) Fertil Steril , vol.62 , pp. 468-76
    • Olivennes, F.1    Franchin, R.2    Bouchard, P.3
  • 11
    • 17544399958 scopus 로고    scopus 로고
    • Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: A prospective uncontrolled phase III study
    • Felberbaum RE, Albano C, Ludwig M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000 15 : 1015 20.
    • (2000) Hum Reprod , vol.15 , pp. 1015-20
    • Felberbaum, R.E.1    Albano, C.2    Ludwig, M.3
  • 12
    • 0034053260 scopus 로고    scopus 로고
    • Ovarian stimulation with HMG: Results of a prospective randomised phase III European study comparing the luteinising hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
    • Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomised phase III European study comparing the luteinising hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000 15 : 526 31.
    • (2000) Hum Reprod , vol.15 , pp. 526-31
    • Albano, C.1    Felberbaum, R.E.2    Smitz, J.3
  • 13
    • 0031661436 scopus 로고    scopus 로고
    • The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
    • Olivennes F, Alvarez S, Bouchard P, et al. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998 13 : 2411 14.
    • (1998) Hum Reprod , vol.13 , pp. 2411-14
    • Olivennes, F.1    Alvarez, S.2    Bouchard, P.3
  • 14
    • 0035142762 scopus 로고    scopus 로고
    • Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women
    • Erb K, Klipping C, Duijkers I, et al. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 2001 75 : 316 23.
    • (2001) Fertil Steril , vol.75 , pp. 316-23
    • Erb, K.1    Klipping, C.2    Duijkers, I.3
  • 15
    • 0037561013 scopus 로고    scopus 로고
    • Cetrotide International Study Groups. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing LH surges: Report of two large multicentre, multinational, phase IIIb clinical experiences
    • Olivennes F, Diedrich K, Frydman R, et al. Cetrotide International Study Groups. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003 6 : 432 8.
    • (2003) Reprod Biomed Online , vol.6 , pp. 432-8
    • Olivennes, F.1    Diedrich, K.2    Frydman, R.3
  • 16
    • 0033816489 scopus 로고    scopus 로고
    • Is endometrial pre-treatment of value in improving the outcome of trans-cervical resection of the endometrium?
    • Rai VS, Gillmer MDG, Gray W. Is endometrial pre-treatment of value in improving the outcome of trans-cervical resection of the endometrium? Hum Reprod 2000 15 : 1989 92.
    • (2000) Hum Reprod , vol.15 , pp. 1989-92
    • Rai, V.S.1    Gillmer, M.D.G.2    Gray, W.3
  • 17
    • 0343632342 scopus 로고    scopus 로고
    • Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: A large randomised, double blind study
    • Donnez J, Vilos G, Gannon MJ, et al. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomised, double blind study. Fertil Steril 1997 68 : 29 6.
    • (1997) Fertil Steril , vol.68 , pp. 29-6
    • Donnez, J.1    Vilos, G.2    Gannon, M.J.3
  • 18
    • 20244374949 scopus 로고
    • Scottish Hysteroscopy Audit Group. a Scottish audit of hysteroscopic surgery for menorrhagia: Complications and follow up
    • Kitchener HC. Scottish Hysteroscopy Audit Group. A Scottish audit of hysteroscopic surgery for menorrhagia: complications and follow up. Br J Obstet Gynaecol : 1995 102 : 249 54.
    • (1995) Br J Obstet Gynaecol , vol.102 , pp. 249-54
    • Kitchener, H.C.1
  • 19
    • 33644878357 scopus 로고    scopus 로고
    • Endometrial destruction techniques for heavy menstrual bleeding
    • CD001501.
    • Lethaby A, Hickey M, Garry R. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2005 CD001501.
    • (2005) Cochrane Database Syst Rev
    • Lethaby, A.1    Hickey, M.2    Garry, R.3
  • 20
    • 0030712967 scopus 로고    scopus 로고
    • A national survey of the complications of endometrial destruction for menstrual disorders: The MISTLETOE study. Minimally Invasive Surgical Techniques-Laser, EndoThermal or Endoresection
    • Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally Invasive Surgical Techniques-Laser, EndoThermal or Endoresection. Br J Obstet Gynaecol 1997 104 : 1351 9.
    • (1997) Br J Obstet Gynaecol , vol.104 , pp. 1351-9
    • Overton, C.1    Hargreaves, J.2    Maresh, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.